Learn more about our Pipeline Strategy practice
Your pharmaceutical brands and medical products may not be generating returns that maximize your company’s substantial R&D and marketing investments. With market conditions creating higher barriers to commercial success, the pressures on R&D and marketing executives are becoming only more acute.
ZS helps life science companies increase the commercial success of their product pipelines. We help you determine what therapy areas to develop, what products in your portfolio will maximize your R&D investment and how to maximize sales through incorporating market input early in development.
ZS’s Pipeline Strategy services helps you:
Create a portfolio strategy that balances risk and return for the short and long term
By Dean Summerfield, Mike Voth, Emily Jin
The pharmaceutical industry is still seeking solutions to reverse the declining R&D productivity of the last decade. Despite significant increases in investment, few companies can view their portfolio pipelines with confidence.
By Aaron Mitchell, Kevin McCarl, Mary Ann Godwin
This paper introduces the OPEN approach, which can help product development teams design products that achieve their full commercial potential while balancing technical and regulatory concerns.